Palisade Bio announced that European Patent Office, EPO, has issued a decision to grant notice for patent number 4,157,853 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” Based on the intention to grant notice, the Company expects the EPO to issue a patent July 31, 2024. In addition to this European patent and recently allowed Canadian patent, the Company continues to strengthen its global intellectual property portfolio surrounding PALI-2108 with submitted and planned submissions of additional patent applications. Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs. This patent family provides Composition of Matter coverage beyond 2042. PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis and PALI-1908 is in development to treat patients with active fibro stenotic Crohn’s Disease
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio announces completion of first GMP batch of PALI-2108
- Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
- Palisade Bio to Participate in the Virtual Investor Closing Bell Series
- Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
- Palisade Bio provides update on collaboration with Strand Life Sciences